ArticleCancer gene therapy2004
Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Article in Cancer gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 87 citations in OpenAlex.
- Human adenovirus DNA polymerase is evolutionarily and functionally associated with human telomerase reverse transcriptase based onFrontiers in bioinformatics · 2023Article
- Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter.International journal of molecular sciences · 2022Review
- Review
- Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma.Frontiers in pharmacology · 2021Review
- A Novel Liquid Biopsy Strategy to Detect Small Amounts of Cancer Cells Using Cancer-Specific Replication Adenoviruses.Journal of clinical medicine · 2020Review
- Multidisciplinary oncolytic virotherapy for gastrointestinal cancer.Annals of gastroenterological surgery · 2019Review
- Functional comparison of the human epidermal growth factor receptor and telomerase reverse transcriptase promoters in canine tumor cells.The Journal of veterinary medical science · 2019Article
- Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.Journal of bone oncology · 2017Review
- Oncolytic viruses: adenoviruses.Virus genes · 2017Review
- MR molecular imaging of tumours using ferritin heavy chain reporter gene expression mediated by the hTERT promoter.European radiology · 2016Article
- Gene Therapies for Cancer: Strategies, Challenges and Successes.Journal of cellular physiology · 2015Review
- Oncolytic adenoviruses: A thorny path to glioma cure.Genes & diseases · 2014Article
- Is telomerase a viable target in cancer?Mutation research · 2012Review
- Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Advances in cancer research · 2012Review
- Targeting telomerase-expressing cancer cells.Journal of cellular and molecular medicine · 2011Review
- Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.Journal of cancer research and clinical oncology · 2011Article
- Anti-tumor effects of adenovirus containing human growth hormone sequences in a mouse model of human ovarian cancer.Endocrine · 2010Article
- Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers.Cancer science · 2008Review
- A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.Cancer gene therapy · 2008Article
- Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma.World journal of gastroenterology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human telomerase reverse transcriptase (hTERT) promoter is known to selectively drive transgene expression in many human cancer cells expressing hTERT, the catalytic component of the telomerase ribonucleoprotein complex. We have created a conditionally replicative adenovirus where the viral E1A gene, which is required for viral replication, is under the control of the hTERT promoter (AdhTERTp-E1A). In vitro studies with AdhTERTp-E1A virus on a variety of normal and tumor cell lines have shown that viral genome replication and productive infection is primarily restricted to telomerase-positive tumor cells. Lytic replication was not observed in normal primary fibroblast and epithelial cell lines tested. In vivo administration of the virus into nude mice bearing human liver or prostate tumor xenografts produced significant tumor reduction and, in some cases, resulted in complete tumor regression. AdhTERTp-E1A virus did not actively express E1A in normal mouse liver, in contrast to a control oncolytic vector in which the CMV promoter (AdCMVp-E1A) was driving the E1A gene. In addition, AdhTERTp-E1A virus produced no apparent toxicity to the liver in systemically injected mice. The hTERT promoter-driven oncolytic virus also produced significantly less toxicity to freshly cultured human hepatocytes. These studies demonstrate that an oncolytic virus driven by the telomerase promoter can be used to effectively kill a wide variety of cancer cell types and has the potential to treat primary and metastatic cancer of diverse origins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.